107 related articles for article (PubMed ID: 7763310)
1. Azatoxin derivatives with potent and selective action on topoisomerase II.
Leteurtre F; Sackett DL; Madalengoitia J; Kohlhagen G; MacDonald T; Hamel E; Paull KD; Pommier Y
Biochem Pharmacol; 1995 May; 49(9):1283-90. PubMed ID: 7763310
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
Solary E; Leteurtre F; Paull KD; Scudiero D; Hamel E; Pommier Y
Biochem Pharmacol; 1993 Jun; 45(12):2449-56. PubMed ID: 8392342
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines.
Eymin B; Solary E; Chevillard S; Dubrez L; Goldwasser F; Duchamp O; Genne P; Leteurtre F; Pommier Y
Int J Cancer; 1995 Oct; 63(2):268-75. PubMed ID: 7591216
[TBL] [Abstract][Full Text] [Related]
4. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
Leteurtre F; Madalengoitia J; Orr A; Guzi TJ; Lehnert E; Macdonald T; Pommier Y
Cancer Res; 1992 Aug; 52(16):4478-83. PubMed ID: 1322792
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
7. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents.
Terada T; Fujimoto K; Nomura M; Yamashita J; Kobunai T; Takeda S; Wierzba K; Yamada Y; Yamaguchi H
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2720-7. PubMed ID: 1334447
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
9. Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms.
van Hille B; Perrin D; Hill BT
Anticancer Drugs; 1999 Jul; 10(6):551-60. PubMed ID: 10885903
[TBL] [Abstract][Full Text] [Related]
10. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
11. New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
La Regina G; Bai R; Coluccia A; Naccarato V; Famiglini V; Nalli M; Masci D; Verrico A; Rovella P; Mazzoccoli C; Da Pozzo E; Cavallini C; Martini C; Vultaggio S; Dondio G; Varasi M; Mercurio C; Hamel E; Lavia P; Silvestri R
Eur J Med Chem; 2018 May; 152():283-297. PubMed ID: 29730191
[TBL] [Abstract][Full Text] [Related]
12. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization.
Gastpar R; Goldbrunner M; Marko D; von Angerer E
J Med Chem; 1998 Dec; 41(25):4965-72. PubMed ID: 9836614
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
Goldbrunner M; Loidl G; Polossek T; Mannschreck A; von Angerer E
J Med Chem; 1997 Oct; 40(22):3524-33. PubMed ID: 9357519
[TBL] [Abstract][Full Text] [Related]
14. Application of GA-MLR for QSAR Modeling of the Arylthioindole Class of Tubulin Polymerization Inhibitors as Anticancer Agents.
Ahmadi S; Habibpour E
Anticancer Agents Med Chem; 2017; 17(4):552-565. PubMed ID: 27528182
[TBL] [Abstract][Full Text] [Related]
15. Identification of potent virtual leads and ADME prediction of isoxazolidine podophyllotoxin derivatives as topoisomerase II and tubulin inhibitors.
Bkhaitan MM; Mirza AZ; Shamshad H; Ali HI
J Mol Graph Model; 2017 May; 73():74-93. PubMed ID: 28242581
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
[TBL] [Abstract][Full Text] [Related]
17. 4- and 5-aroylindoles as novel classes of potent antitubulin agents.
Liou JP; Wu CY; Hsieh HP; Chang CY; Chen CM; Kuo CC; Chang JY
J Med Chem; 2007 Sep; 50(18):4548-52. PubMed ID: 17685504
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
Li W; Shuai W; Sun H; Xu F; Bi Y; Xu J; Ma C; Yao H; Zhu Z; Xu S
Eur J Med Chem; 2019 Feb; 163():428-442. PubMed ID: 30530194
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors.
Kamal A; Srinivasa Reddy T; Polepalli S; Shalini N; Reddy VG; Subba Rao AV; Jain N; Shankaraiah N
Bioorg Med Chem; 2014 Oct; 22(19):5466-75. PubMed ID: 25131956
[TBL] [Abstract][Full Text] [Related]
20. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
